Ozempic vs Wegovy vs Mounjaro in India
Ozempic, Wegovy, and Mounjaro are not interchangeable — and the right one depends on your metabolic phenotype, not the ad you saw last.
All three names get thrown around as if they’re the same drug. They are not. Ozempic and Wegovy share the same molecule (semaglutide) but are approved for different indications. Mounjaro is a different molecule entirely (tirzepatide), with a different mechanism and a different weight-loss ceiling. This page breaks down what each one actually does in the body, how they compare head-to-head, what they cost in India, and how a doctor decides between them — because at Inteledoc, that decision is never made by brand preference.
Prescription-only. All three are prescription medications in India. This page is educational, not a recommendation for you individually — that requires a consultation, a metabolic assessment, and a doctor's judgement.
For the full clinical picture on how GLP-1 therapy is prescribed at Inteledoc, see our GLP-1 Weight Loss Programme.
Quick answer, before the detail
If you only remember one thing: tirzepatide (Mounjaro) tends to produce the largest weight loss on average, semaglutide (Ozempic/Wegovy) is the more established and widely available option, and the "right" one is a clinical decision based on your labs and phenotype — not a preference call.
What each drug actually is
Ozempic and Wegovy are the same drug, sold under two names for two purposes
Both contain semaglutide. Novo Nordisk markets it as Ozempic for type 2 diabetes and as Wegovy for chronic weight management, at slightly different maximum doses. In India,
Ozempic is the more established, more widely stocked brand — many patients using semaglutide for weight loss in India are, in practice, prescribed Ozempic off-label under a
diabetes/pre-diabetes or metabolic-syndrome indication, since Wegovy’s India stock is inconsistent city to city.
Mounjaro is a different, newer class of drug
Mounjaro’s active molecule, tirzepatide, is a dual agonist — it activates both the GLP-1 receptor and a second receptor called GIP (glucose-dependent insulinotropic polypeptide). This dual action is why tirzepatide tends to outperform semaglutide on weight loss and glycaemic control in head-to-head trial data. It also means tolerability and dosing follow a different curve, which matters for how it’s titrated.
Head-to-head: mechanism, results, and who each suits
Neither drug is “better” in the abstract. Tirzepatide’s dual mechanism gives it an edge on average weight loss and insulin sensitisation, which is why Inteledoc’s doctors lean toward it for insulin-resistant, pre-diabetic, and fatty-liver phenotypes specifically. Semaglutide remains the first-line choice for many patients because of its longer safety track record, broader availability, and strong cardiovascular data — which matters for patients with existing heart-disease risk.
Cost in India: what you’re actually paying for
Medication cost is separate from any programme or doctor consultation fee, and it varies by dose, brand, and pharmacy.
Two things worth knowing before you compare prices online: first, cost climbs as your dose is titrated up over the first 3–5 months, so your first month is never representative of your steady-state cost. Second, most Indian health insurance policies do not currently cover GLP-1 medication for a weight-loss indication — coverage is more likely, though not guaranteed, under a diabetes diagnosis. Ask your insurer directly, and ask your doctor for supporting clinical documentation if you plan to file a claim.
How Inteledoc’s doctors actually choose between them
We don’t start with a brand name — we start with a metabolic assessment. A fasting insulin, HOMA-IR, HbA1c, lipid panel, and thyroid profile tell us far more about which drug will work for your biology than any comparison chart can. In broad terms:
- Semaglutide (Ozempic/Wegovy)is usually our first-line recommendation for patients with general insulin resistance, appetite-driven overeating, or elevated cardiovascular
risk where the semaglutide cardiovascular outcome data is directly relevant. - Tirzepatide (Mounjaro) is usually favoured for patients with more pronounced insulin resistance, pre-diabetes, high triglycerides, or fatty liver — phenotypes where the added
GIP mechanism produces a measurably better result. - Availability and cost are real-world constraints we factor in openly with every patient — the “better” drug on paper is not helpful if it can’t be reliably sourced in your city.
This is the same phenotype-first approach used across the Inteledoc GLP-1 programme: labs and clinical picture first, medication decision second, and never a prescription without a consultation.
Side effects: how the three compare
Gastrointestinal side effects — nausea, reduced appetite, occasional vomiting or diarrhoea — are common to all three drugs, particularly during dose escalation, and typically ease over the first 4–8 weeks at each dose step. Reported tolerability between semaglutide and tirzepatide is broadly similar in trial data, though some patients find one more tolerable than the other individually — which is one more reason dosing decisions and titration pace need to be doctor-supervised rather than self-managed. For a full breakdown of what to expect and how side effects are managed, see the GLP-1 programme page.
Frequently asked questions
The right GLP-1 medication is the one that matches your biology — not the one trending on social media.
Ozempic, Wegovy, and Mounjaro all work. Which one works best for you depends on insulin resistance, appetite phenotype, cardiovascular risk, and what’s reliably available near you — all of which your doctor should assess before writing a prescription.